Alluvi, formerly BI 4744, represents a notable development in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable results in research trials, https://exactlybookmarks.com/story22073187/alluvi-a-detailed-investigation-into-retatrutide-s-possibilities